Dergiler / Marmara Medical Journal / 2026 / Volume: 28 Issue: 1 Special Issue

-

Proceedings in oncology: Aren’t we back to the future?

Sayfa
—
Yayın Tarihi
2015-09-30
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗

Özet

-

Abstract

Three weeks ago Pamir Atagunduz, the Chief Editor of Marmara Medical Journal, talked to me about his plans for the Journal in the upcoming years with great excitement and enthusiasm. I felt honored when he asked if I would be interested in becoming the invited editor for the first of the “Special Issue” series of Marmara Medical Journal. The same day I started to plan how to accomplish an oncology issue in a very short period of time. When I called Esra Saglam, asking for a review due in 3 weeks, not only she said yes, but also encouraged me with her great ideas. Here, I would especially thank to all of the authors in this issue for writing these manuscripts despite their very busy schedule. Also, I owe special thanks to Bruce Minsky for his positive approach in contributing to our Journal. In addition to the current information regarding positive interaction between immunotherapy and radiotherapy you will find the latest developments on treatment of various cancers in this “Special Issue - Oncology “.

🔖

Bu Makaleye Atıf Yap

Yumuk, P. F. (2015). -. Marmara Medical Journal, Volume: 28 Issue: 1 Special Issue. https://doi.org/10.5472/mmj.37882

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (26)

  1. Minsky B. Advances in the management of esophageal
  2. cancer. Marmara Med J 2015; 28 (Special Issue 1):3-10.
  3. doi:10.5472/mmj.10059
  4. Dane F. What to expect from HER-2 directed therapies
  5. in advanced gastric cancer? Marmara Med J 2015; 28
  6. (Special Issue 1):11-15. doi:10.5472/mmj.87204
  7. Akgun Z, Saglam EK. Neoadjuvant treatment in locally
  8. advanced rectal cancer. Marmara Med J 2015; 28
  9. (Special Issue 1):16-20. doi:10.5472/mmj.43321
  10. Igdem S. Treatment of prostate cancer by hypofractionated
  11. radiotherapy. Marmara Med J 2015; 28 (Special Issue:21-23. doi:10.5472/mmj.11680
  12. Bavbek S. How to approach castration-resistant prostate
  13. cancer? Marmara Med J 2015; 28 (Special Issue 1):24-
  14. doi:10.5472/mmj.80248
  15. http://www.accessdata.fda.gov/drugsatfda_docs/
  16. appletter/2015/207103Orig1s000ltr.pdf
  17. Aktas B. CDK inhibitors in hormone receptor positive
  18. advanced breast cancer. Marmara Med J 2015; 28
  19. (Special Issue 1):35-39. doi:10.5472/mmj.77406
  20. Anacak Y, Kamer S, Sert F. Combining radiotherapy with
  21. immunotherapy. Marmara Med J 2015; 28 (Special Issue:40-44. doi:10.5472/mmj.34632
  22. ht tp: / /www.fda.gov/NewsEvents/Newsroom/
  23. PressAnnouncements/ucm436534.htm
  24. https://clinicaltrials.gov/ct2/show/NCT01642004?term
  25. =CheckMate+017&rank=1
  26. http://www.medscape.com/viewarticle/840890